moderate renal impairment (creatinine clearence < 60 ml/ min) hypothyroidism personal or family history of hereditary muscular disorders previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate alcohol abuse situations where an increase in plasma levels may occur Japanese and Chinese patients concomitant use of fibrates.